Matrix Metalloproteinases Cause Peritoneal Injury in Peritoneal Dialysis

Hirahara, Ichiro; Akimoto, Tetsu; Morishita, Yoshiyuki; Saito, Osamu; Muto, Shigeaki; Kusano, Eiji

doi:10.5772/24227

Cited by 1 publication

(1 citation statement)

References 47 publications

(70 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Matrix metalloproteinase-2 has a variety of roles in the peritoneal cavity, which include degradation of the endothelial basal lamina (23) and type IV collagen, and promotion of angiogenesis and basement membrane injury (24). These changes functionally manifest as fast solute transport rate.…”

Section: Discussionmentioning

confidence: 99%

Higher Dialysate Matrix Metalloproteinase-2 Levels are Associated with Peritoneal Membrane Dysfunction

et al. 2016

View full text Add to dashboard Cite

♦ Background: Peritoneal dialysis (PD) patients develop progressive and cumulative peritoneal injury with longer time spent on PD. The present study aimed to a) describe the trend of peritoneal injury biomarkers, matrix metalloproteinase-2 (MMP-2) and tissue inhibitor of metalloproteinase-1 (TIMP-1), in incident PD patients, b) to explore the capacity of dialysate MMP-2 to predict peritoneal solute transport rate (PSTR) and peritonitis, and c) to evaluate the influence of neutral pH, low glucose degradation product (GDP) PD solution on these outcomes. ♦ Methods: The study included 178 participants from the balANZ trial who had at least 1 stored dialysate sample. Changes in PSTR and peritonitis were primary outcome measures, and the utility of MMP-2 in predicting these outcomes was analyzed using multilevel linear regression and multilevel Poisson regression, respectively. KEY WORDS: Biocompatible; glucose degradation products; matrix metalloproteinase-2; peritoneal dialysis; peritoneal solute transport rate; peritonitis; tissue inhibitor of metalloproteinase-1.

show abstract

Section: Discussionmentioning

confidence: 99%